TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06514794: A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Sponsor: Allotera Therapeutics · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 125 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$3,049,200

Rescue Site Savings

+$2,032,800

Unlock Full NCT06514794 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06514794 Rescue Dossier →